APP and fragile X syndrome: It will be of interest to study clinically relevant behavioral alterations in mouse models of FXS and Alzheimer’s disease in response to AFC03127 in future studies, particularly considering the pivotal role of GSK3 in APP biology and the wide range of phenotypes rescued in Fmr1KO mice in response to GSK3 inhibitors (Rizk et al., 2021; Figure 1).